Barbara E Bierer

Barbara Emily Bierer, MD

Professor of Medicine (Pediatrics), HMS
Member, HMS Center for Bioethics

Barbara Bierer, MD is a Professor of Medicine (Pediatrics) at Harvard Medical School (HMS), and a hematologist/oncologist at the Brigham and Women's Hospital (BWH). She received her MD from HMS. She is the director of the Regulatory Foundations, Law and Ethics Program of the Harvard Catalyst, the Harvard Clinical and Translational Science Award, and the director of regulatory policy, SMART IRB. Dr. Bierer co-founded and now leads the Multi-Regional Clinical Trials Center of BWH and Harvard (MRCT Center), a University-wide and collaborative effort to improve the ethics, conduct, and regulatory environment for multi-site, multi-national clinical trials. She is a co-founder of COVID-19 Collaboration Platform, a platform for cooperation in research. In 2017, the MRCT Center launched the non-profit Vivli, a global clinical research data sharing platform. From 2003-2014, she served as Senior Vice President, Research, at BWH and was the institutional official for human subjects and animal research, for biosafety and for research integrity at the BWH. She initiated the Brigham Research Institute and the Innovation Hub (iHub), a focus for entrepreneurship and innovation. Dr. Bierer established and directed the Center for Faculty Development and Diversity at the BWH; for these efforts, she was the first recipient of the HMS Harold Amos Faculty Diversity Award.

Publications View
T cell adhesion, avidity regulation and signaling: a molecular analysis of CD2.
Authors: Authors: Bierer BE, Hahn WC.
Semin Immunol
View full abstract on Pubmed
Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide.
Authors: Authors: Wheeler C, Strawderman M, Ayash L, Churchill WH, Bierer BE, Elias A, Gilliland DG, Antman K, Guinan EC, Eder JP, et al.
J Clin Oncol
View full abstract on Pubmed
The complete sequences of plasmids pFNeo and pMH-Neo: convenient expression vectors for high-level expression of eukaryotic genes in hematopoietic cell lines.
Authors: Authors: Hahn WC, Menzin E, Saito T, Germain RN, Bierer BE.
Gene
View full abstract on Pubmed
A role for calcineurin in degranulation of murine cytotoxic T lymphocytes.
Authors: Authors: Dutz JP, Fruman DA, Burakoff SJ, Bierer BE.
J Immunol
View full abstract on Pubmed
Signal transduction pathways involved in T cell receptor-induced regulation of CD2 avidity for CD58.
Authors: Authors: Hahn WC, Burakoff SJ, Bierer BE.
J Immunol
View full abstract on Pubmed
Association of CD2 with tubulin. Evidence for a role of the cytoskeleton in T cell activation.
Authors: Authors: Offringa R, Bierer BE.
J Biol Chem
View full abstract on Pubmed
Cell-mediated immunity.
Authors: Authors: Goust JM, Bierer B.
Immunol Ser
View full abstract on Pubmed
CD4, CD8 and CD2 in T cell adhesion and signaling.
Authors: Authors: Collins TL, Hahn WC, Bierer BE, Burakoff SJ.
Curr Top Microbiol Immunol
View full abstract on Pubmed
Correlation of calcineurin phosphatase activity and programmed cell death in murine T cell hybridomas.
Authors: Authors: Fruman DA, Mather PE, Burakoff SJ, Bierer BE.
Eur J Immunol
View full abstract on Pubmed
Effects of cyclosporin A and FK506 on Fc epsilon receptor type I-initiated increases in cytokine mRNA in mouse bone marrow-derived progenitor mast cells: resistance to FK506 is associated with a deficiency in FK506-binding protein FKBP12.
Authors: Authors: Kaye RE, Fruman DA, Bierer BE, Albers MW, Zydowsky LD, Ho SI, Jin YJ, Castells MC, Schreiber SL, Walsh CT, et al.
Proc Natl Acad Sci U S A
View full abstract on Pubmed